JP2007514646A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514646A5 JP2007514646A5 JP2006532511A JP2006532511A JP2007514646A5 JP 2007514646 A5 JP2007514646 A5 JP 2007514646A5 JP 2006532511 A JP2006532511 A JP 2006532511A JP 2006532511 A JP2006532511 A JP 2006532511A JP 2007514646 A5 JP2007514646 A5 JP 2007514646A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- formula
- compound
- sch
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 23
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 2
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47173903P | 2003-05-20 | 2003-05-20 | |
| US60/471,739 | 2003-05-20 | ||
| PCT/US2004/013314 WO2004103272A2 (en) | 2003-05-20 | 2004-05-20 | Improved cytotoxic agents comprising new maytansinoids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000052A Division JP5563673B2 (ja) | 2003-05-20 | 2013-01-04 | 新規メイタンシノイドを含む改良された細胞毒性薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514646A JP2007514646A (ja) | 2007-06-07 |
| JP2007514646A5 true JP2007514646A5 (enExample) | 2007-09-27 |
| JP5208420B2 JP5208420B2 (ja) | 2013-06-12 |
Family
ID=33476883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532511A Expired - Lifetime JP5208420B2 (ja) | 2003-05-20 | 2004-05-20 | 新規メイタンシノイドを含む改良された細胞毒性薬 |
| JP2013000052A Expired - Lifetime JP5563673B2 (ja) | 2003-05-20 | 2013-01-04 | 新規メイタンシノイドを含む改良された細胞毒性薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000052A Expired - Lifetime JP5563673B2 (ja) | 2003-05-20 | 2013-01-04 | 新規メイタンシノイドを含む改良された細胞毒性薬 |
Country Status (27)
| Country | Link |
|---|---|
| EP (4) | EP3524611B1 (enExample) |
| JP (2) | JP5208420B2 (enExample) |
| KR (1) | KR101145506B1 (enExample) |
| CN (2) | CN101186613B (enExample) |
| AU (1) | AU2004240541B2 (enExample) |
| BR (2) | BRPI0419348B8 (enExample) |
| CA (1) | CA2525130C (enExample) |
| CL (1) | CL2012000651A1 (enExample) |
| CO (1) | CO5660276A2 (enExample) |
| CR (1) | CR20170291A (enExample) |
| CY (2) | CY1117161T1 (enExample) |
| DK (2) | DK1651162T3 (enExample) |
| EA (1) | EA010909B1 (enExample) |
| EC (1) | ECSP056149A (enExample) |
| ES (2) | ES2559670T3 (enExample) |
| HR (2) | HRP20160046T1 (enExample) |
| HU (2) | HUE054074T2 (enExample) |
| IL (6) | IL171170A (enExample) |
| LT (1) | LT3524611T (enExample) |
| MX (3) | MX370281B (enExample) |
| NO (1) | NO339597B1 (enExample) |
| NZ (1) | NZ542695A (enExample) |
| PL (2) | PL3524611T3 (enExample) |
| PT (2) | PT3524611T (enExample) |
| SI (2) | SI3524611T1 (enExample) |
| WO (1) | WO2004103272A2 (enExample) |
| ZA (1) | ZA200507845B (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170291A (es) * | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinóides |
| HUE025449T2 (en) | 2004-12-09 | 2016-04-28 | Janssen Biotech Inc | Immunoconjugates against Integrin, a method for their preparation and use |
| AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| US20090214536A1 (en) | 2005-04-07 | 2009-08-27 | Guoying Yu | CACNA1E in Cancer Diagnosis, Detection and Treatment |
| KR20070120156A (ko) * | 2005-04-15 | 2007-12-21 | 이뮤노젠 아이엔씨 | 종양에서 이종 또는 혼성 세포 집단의 제거 방법 |
| CN101267841B (zh) * | 2005-08-24 | 2012-10-10 | 免疫原公司 | 制备美登木素生物碱抗体缀合物的方法 |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| EP2004221A2 (en) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Anti-tumor cell antigen antibody therapeutics |
| WO2007120787A2 (en) | 2006-04-13 | 2007-10-25 | Novartis Vaccines & Diagnostics, Inc. | Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression |
| US8846005B2 (en) | 2007-03-14 | 2014-09-30 | Novartis Ag | APCDD1 inhibitors for treating, diagnosing or detecting cancer |
| MX2010011808A (es) | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| KR20120080611A (ko) * | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
| DK2488873T3 (en) | 2009-10-16 | 2015-11-09 | Novartis Ag | Biomarkers for pharmacodynamic tumor responses |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| US8637641B2 (en) | 2010-07-29 | 2014-01-28 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP2621954A1 (en) | 2010-10-01 | 2013-08-07 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| MX2013005046A (es) * | 2010-11-03 | 2013-12-12 | Immunogen Inc | Agentes citotoxicos que comprenden nuevos derivados de ansamitocina. |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| RU2451010C1 (ru) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия |
| MX339927B (es) | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP2766392B1 (en) | 2011-10-10 | 2019-07-17 | Xencor, Inc. | A method for purifying antibodies |
| BR122021022582B1 (pt) * | 2012-09-26 | 2023-01-10 | Immunogen, Inc | Método de preparação de intermediários na síntese de maitansinoides |
| SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| CN103933575B (zh) | 2013-01-23 | 2017-09-29 | 上海新理念生物医药科技有限公司 | 一种三齿型连接子及其应用 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| KR102413494B1 (ko) | 2013-03-15 | 2022-06-24 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
| CA2906927C (en) | 2013-03-15 | 2021-07-13 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| SI3122781T1 (sl) | 2014-03-28 | 2020-03-31 | Xencor, Inc. | Bispecifična protitelesa, ki se vežejo na CD38 in CD3 |
| CN104974252B (zh) * | 2014-04-01 | 2020-04-24 | 三生国健药业（上海）股份有限公司 | 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途 |
| JP6602834B2 (ja) | 2014-06-30 | 2019-11-06 | ターベダ セラピューティクス インコーポレイテッド | 標的化コンジュゲートならびにその粒子及び製剤 |
| WO2016014984A1 (en) | 2014-07-24 | 2016-01-28 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| JP2017526682A (ja) | 2014-09-02 | 2017-09-14 | イミュノジェン， インコーポレイテッド | 抗体薬物複合体組成物の製剤化方法 |
| JP2017527562A (ja) | 2014-09-03 | 2017-09-21 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体 |
| ES2815353T3 (es) | 2014-09-03 | 2021-03-29 | Immunogen Inc | Derivados de benzodiazepina citotóxicos |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
| HUE055115T2 (hu) | 2014-11-26 | 2021-10-28 | Xencor Inc | CD3-at és CD20-at kötõ heterodimer antitestek |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
| EP3308801A4 (en) | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-ACTIVE CONJUGATE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| JP7057278B2 (ja) | 2015-10-28 | 2022-04-19 | ターベダ セラピューティクス インコーポレイテッド | Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤 |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| US10501543B2 (en) | 2016-10-14 | 2019-12-10 | Xencor, Inc. | IL15/IL15Rα heterodimeric Fc-fusion proteins |
| CN117731591A (zh) | 2016-11-21 | 2024-03-22 | 艾里奥治疗公司 | 大试剂的透皮递送 |
| CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| TW202506199A (zh) | 2017-02-28 | 2025-02-16 | 美商伊繆諾金公司 | 具有自分解肽連接子之類美登素衍生物及其結合物 |
| GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| MA51291A (fr) | 2017-12-19 | 2020-10-28 | Xencor Inc | Protéines de fusion il-2 fc modifiées |
| EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| CR20210047A (es) | 2018-07-02 | 2021-05-21 | Amgen Inc | Proteína de unión al antígeno anti-steap1 |
| US11857638B2 (en) | 2018-07-27 | 2024-01-02 | Promega Corporation | Quinone-containing conjugates |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| BR112021016955A2 (pt) | 2019-03-01 | 2021-11-23 | Xencor Inc | Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico |
| FI3956332T3 (fi) * | 2019-04-18 | 2023-05-09 | Indena Spa | Diastereoselektiivinen menetelmä tiolia tai disulfidia sisältävien maytansinoidiestereiden ja niiden välituotteiden valmistamiseksi |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| CR20220058A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos |
| CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| MX2023010499A (es) | 2021-03-09 | 2023-09-18 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cldn6. |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| WO2023089314A1 (en) | 2021-11-18 | 2023-05-25 | Oxford Biotherapeutics Limited | Pharmaceutical combinations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
| HK1049787B (en) * | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| BR0212641A (pt) * | 2001-09-05 | 2005-04-12 | Genentech Inc | Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso |
| AU2004247015B2 (en) * | 2003-05-14 | 2010-12-16 | Immunogen, Inc. | Drug conjugate composition |
| CR20170291A (es) * | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinóides |
| CN103554261B (zh) * | 2003-07-21 | 2017-03-01 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
-
2004
- 2004-05-20 CR CR20170291A patent/CR20170291A/es unknown
- 2004-05-20 KR KR1020057022166A patent/KR101145506B1/ko not_active Expired - Lifetime
- 2004-05-20 DK DK04750945.0T patent/DK1651162T3/en active
- 2004-05-20 CA CA2525130A patent/CA2525130C/en not_active Expired - Lifetime
- 2004-05-20 HU HUE19160750A patent/HUE054074T2/hu unknown
- 2004-05-20 HR HRP20160046TT patent/HRP20160046T1/hr unknown
- 2004-05-20 PT PT191607506T patent/PT3524611T/pt unknown
- 2004-05-20 MX MX2016009879A patent/MX370281B/es unknown
- 2004-05-20 EP EP19160750.6A patent/EP3524611B1/en not_active Expired - Lifetime
- 2004-05-20 EP EP15190436.4A patent/EP3031810B1/en not_active Expired - Lifetime
- 2004-05-20 WO PCT/US2004/013314 patent/WO2004103272A2/en not_active Ceased
- 2004-05-20 HU HUE04750945A patent/HUE028314T2/en unknown
- 2004-05-20 EA EA200501836A patent/EA010909B1/ru unknown
- 2004-05-20 CN CN200710194150.0A patent/CN101186613B/zh not_active Expired - Lifetime
- 2004-05-20 SI SI200432508T patent/SI3524611T1/sl unknown
- 2004-05-20 EP EP04750945.0A patent/EP1651162B1/en not_active Expired - Lifetime
- 2004-05-20 MX MX2013008224A patent/MX340862B/es unknown
- 2004-05-20 BR BRPI0419348A patent/BRPI0419348B8/pt active IP Right Grant
- 2004-05-20 ES ES04750945.0T patent/ES2559670T3/es not_active Expired - Lifetime
- 2004-05-20 PT PT47509450T patent/PT1651162E/pt unknown
- 2004-05-20 PL PL19160750T patent/PL3524611T3/pl unknown
- 2004-05-20 ES ES19160750T patent/ES2863498T3/es not_active Expired - Lifetime
- 2004-05-20 PL PL04750945T patent/PL1651162T3/pl unknown
- 2004-05-20 MX MXPA05011811A patent/MXPA05011811A/es active IP Right Grant
- 2004-05-20 AU AU2004240541A patent/AU2004240541B2/en not_active Expired
- 2004-05-20 BR BRPI0410748A patent/BRPI0410748B8/pt not_active IP Right Cessation
- 2004-05-20 EP EP20216572.6A patent/EP3851126A1/en active Pending
- 2004-05-20 SI SI200432295T patent/SI1651162T1/sl unknown
- 2004-05-20 NZ NZ542695A patent/NZ542695A/en not_active IP Right Cessation
- 2004-05-20 JP JP2006532511A patent/JP5208420B2/ja not_active Expired - Lifetime
- 2004-05-20 LT LTEP19160750.6T patent/LT3524611T/lt unknown
- 2004-05-20 CN CNA2004800134886A patent/CN1956722A/zh active Pending
- 2004-05-20 DK DK19160750.6T patent/DK3524611T3/da active
-
2005
- 2005-09-28 ZA ZA200507845A patent/ZA200507845B/en unknown
- 2005-09-29 IL IL171170A patent/IL171170A/en active IP Right Grant
- 2005-11-03 CO CO05112351A patent/CO5660276A2/es unknown
- 2005-11-10 EC EC2005006149A patent/ECSP056149A/es unknown
- 2005-12-19 NO NO20056039A patent/NO339597B1/no unknown
-
2011
- 2011-06-30 IL IL213876A patent/IL213876A/en active IP Right Grant
-
2012
- 2012-03-14 CL CL2012000651A patent/CL2012000651A1/es unknown
- 2012-11-27 IL IL223297A patent/IL223297A/en active IP Right Grant
-
2013
- 2013-01-04 JP JP2013000052A patent/JP5563673B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-30 IL IL231810A patent/IL231810A/en active IP Right Grant
-
2015
- 2015-05-19 IL IL238894A patent/IL238894A/en active IP Right Grant
- 2015-09-06 IL IL241211A patent/IL241211B/en active IP Right Grant
-
2016
- 2016-01-21 CY CY20161100067T patent/CY1117161T1/el unknown
-
2021
- 2021-03-19 HR HRP20210464TT patent/HRP20210464T1/hr unknown
- 2021-03-26 CY CY20211100265T patent/CY1124278T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514646A5 (enExample) | ||
| EA200800476A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| EA200300559A1 (ru) | Производные цианопирролидина | |
| WO2005105732A8 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2007508359A5 (enExample) | ||
| TW200519088A (en) | Aryl or heteroaryl amide compounds | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| EP1325921A3 (en) | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | |
| CY1112997T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟ[1,5-α]ΠΥΡΙΔΙΝΩΝ, Η ΔΙΑΔΙΚΑΣIΑ ΠΑΡΑΣΚΕΥΗΣ ΤΟΥΣ ΚΑΙ ΟΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΑ ΠΕΡΙΕΧΟΥΝ | |
| CY1109222T1 (el) | Παραγωγο συγχωνευμενης κινολινης και χρηση του | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| JP2007531739A5 (enExample) | ||
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| ATE450496T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| JP2010535706A5 (enExample) | ||
| JPS5611718B2 (enExample) | ||
| TNSN07439A1 (en) | Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics | |
| JP2007517826A5 (enExample) | ||
| ATE540675T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| EA200700767A1 (ru) | Способ получения пиразолов | |
| CA2531980A1 (en) | Imide derivatives as therapeutic agents for senile dementia | |
| TW200504071A (en) | 7-(alkenylamino)triazolopyrimidines, their preparation and their use in the control of harmful fungi, and preparations comprising them | |
| EP2511274A3 (en) | Polyamine derivative |